Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

T790M mutation is most common resistant mechanism to epidermal growth factor receptor gene (EGFR) tyrosin kinase inhibitor (TKI). Several third-generation EGFR-mutant selective TKI, such as AZD9291 (AstraZeneca), Rociletinib (Clovis), or HM61713 (Hanmi) have been developed. Acquired resistant C797S mutation was known to be one of the resistance mechanisms of AZD9291, which has not been reported for HM61713 yet. This is the first case report of C797S mutation as resistance mechanism of HM61713.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Thorac Oncol

Title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Publisher: Elsevier BV

ISSN (Electronic): 1556-1380

ISSN (Print): 1556-0864

Publication date (Electronic): Apr 2016

Volume: 11

Issue: 4

Affiliations

[1 ] Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Republic of Korea.

[2 ] Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

[3 ] Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

[4 ] Samsung Genome Institute, Seoul, Republic of Korea; Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

[5 ] Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: silkahn@skku.edu.

Article

Publisher Item ID: S1556-0864(15)00209-9

DOI: 10.1016/j.jtho.2015.12.093

PubMed ID: 26749488

SO-VID: f7fb99ca-6212-45ae-ac23-8f4da7a730f1

History

Keywords: C797S mutation,EGFR,HM61713,T790M mutation

Data availability:

Keywords: C797S mutation, EGFR, HM61713, T790M mutation

Comments

Comment on this article

scite_

Cited by 37

See all cited by

- Version 1